Newly registered injectable medication for Nemera ‘s Safe’n’Sound® syringe
23 septembre 19 | e.bonus | #1516 :: rss
Hulio™ (Adalimumab Biosimilar) (photo on the right), developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. is approved as a biosimilar for the same indications as the reference product, Humira®. This formulation received market authorizations with Terumo proprietary PLAJEX™ pre-filled syringe, in combination with Nemera 1ml Safe’n’Sound add-on safety device.
In the parenteral industry, needlestick injuries are a global concern, all the more with the growing trend of self-administration. According to World Health Organization, over 3 million exposures to blood occur every year, resulting in health, psychological and cost issues.
To ensure adherence and user well-being, Nemera has developed Safe’n’Sound® (photo on the left), a fully passive safety device for prefilled syringes. With an ergonomic and robust design, it helps in preventing needle stick injuries, providing a user-friendly protection for healthcare professionals or patients This add-on device has been developed for healthcare professionals, patients with self-administered prescribed medications, or individuals that assist selfinjecting patients.
Safe’n’Sound® is a customizable platform, compatible with prefilled ISO standard glass syringes as well as PLAJEX™ COP syringe, for 1ml or 2.25ml. Not only does Safe’n’Sound® improve users safety and injection, but also the device complies with the recommendations of the World Health Organization, US FDA (US Federal Needle stick Prevention Act, 2000) and the EU Medical Device Regulation 2017/745 (MDR).
All rights reserved except agreement written by Emballage Digest or mention of the magazine